Abstract
Objective To evaluate brain health through the use of expanded structural measures of reserve, that incorporate pre-existing pathology and cerebrovascular disease burden.
Background Outcome modeling at the time of stroke is a key challenge in patient care. The related concepts of brain health and reserve may help to understand the observed differences in patient outcomes. Effective reserve (eR) quantifies the brain’s capacity to compensate for negative effects, while accounting for pre-existing disease burden. Here, we extend the concept of eR by including measures of white matter hyperintensity (WMH) burden and compare the utility of brain volume and brain parenchymal fraction (BPF) to enhance its modeling capabilities.
Design/Methods Acute ischemic stroke patients from a single center between 2003-2011 with available neuroimaging data were included in this study. Modified Rankin Score (mRS) at 90 days post admission was used to assess functional outcome. Neuroimaging data were analyzed using dedicated deep-learning enabled pipelines to extract measures of WMH, brain, and intracranial volumes (ICV). BPF is given as the ratio of brain volume to ICV. eR is defined as a latent variable using structural equation modeling that includes age, WMH volume, and either BPF or brain volume. Models were compared using Bayes Information Criterion (BIC).
Results 476 patients were eligible for inclusion: median age 65.8 (interquartile range: 55.3-76.3) years, 65.3% male. There was an inverse association between eR and mRS in both brain volume and BPF models (path coefficients: -0.75 and -0.55, respectively; p<0.001). The model utilizing brain volume (BIC=4429.6) outperformed the model using BPF (BIC=4802.2).
Conclusions In this work, we significantly extended the concept of eR and advanced its translational potential. The demonstrated association of higher eR and better post-stroke outcome signifies its potential as a descriptor of brain health, and a protective measure against acute ischemic injury.
Competing Interest Statement
Research reported in this publication was supported by the National Institute of Aging of the National Institutes of Health under award number R21AG083559. NSR is supported by NINDS U19NS115388. RWR serves on a DSMB for a trial sponsored by Rapid Medical, serves as site PI for studies sponsored by Microvention and Penumbra, and receives research grant support from National Institutes of Health (NINDS R25NS065743), Society of Vascular and Interventional Neurology, and Heitman Stroke Foundation. MDS is supported by the Heinz Family Foundation, Heitman Stroke Foundation, and NIA R21AG083559.
Funding Statement
Research reported in this publication was supported by the National Institute of Aging of the National Institutes of Health under award number R21AG083559. NSR is supported by NINDS U19NS115388. RWR serves on a DSMB for a trial sponsored by Rapid Medical, serves as site PI for studies sponsored by Microvention and Penumbra, and receives research grant support from National Institutes of Health (NINDS R25NS065743), Society of Vascular and Interventional Neurology, and Heitman Stroke Foundation. MDS is supported by the Heinz Family Foundation, Heitman Stroke Foundation, and NIA R21AG083559.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Massachusetts General Brigham gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
